Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

------

Squamous cell 3x10(9) 8 Clinical CR, SD per CT

carcinoma (SCC) scan

head & neck

-------------------------------------------------------------------------

Peritoneal 3x10(9) 3 PD

-------------------------------------------------------------------------

Melanoma (eye) 1x10(10) 2 PD

-------------------------------------------------------------------------

Head & neck 1x10(10) 8 PR

-------------------------------------------------------------------------

Nasopharynx 1x10(10) 8 PR

-------------------------------------------------------------------------

Endometrial 3x10(10) 8 SD

-------------------------------------------------------------------------

SCC nasopharynx 3x10(10) 1 PD

-------------------------------------------------------------------------

Head & neck 3x10(10) 2 SD

(laryngeal

carcinoma)

-------------------------------------------------------------------------

Phase II patients

-------------------------------------------------------------------------

Nasopharynx 3x10(10) 8* SD

-------------------------------------------------------------------------

Nasopharynx 3x10(10) 7* PR

with liver mets

-------------------------------------------------------------------------

SCC nasolabial 3x10(10) 5* SD

fold

-------------------------------------------------------------------------

SCC nasopharynx 3x10(10) 4* PR

-------------------------------------------------------------------------

SCC nasopharynx 3x10(10) 2* Too early to eval
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email: